Brain Cancer

Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

The developers of paxalisib will have a Type C meeting with the FDA to discuss its registration as treatment for newly diagnosed glioblastoma.

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.

Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.

Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.

Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

UNITED is the first trial to assess MR-guided weekly adaptive on-line and real-time radiotherapy with clinical target volume margin reductions.

The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.

Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.

Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.

Phase 1 data may warrant further investigation of TLX101 plus external beam radiation therapy for patients with recurrent glioblastoma.

The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.

Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.

Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma.

Phase 3 data from the INDIGO trial support the FDA approval of vorasidenib for select patients with grade 2 astrocytoma or oligodendroglioma.

Developers plan to discuss findings from the phase 2/3 GBM AGILE study with the FDA to determine a potential approval pathway for paxalisib.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.